Title : Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Pub. Date : 2004 Jun 8

PMID : 15184610






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab interferon beta 1 Homo sapiens
2 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab interferon beta 1 Homo sapiens
3 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab interferon beta 1 Homo sapiens
4 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab interferon beta 1 Homo sapiens